DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• High-level CD8+ T cell responses are valuable for prophylactic and therapeutic immunization against infectious diseases.
• Current vaccination strategies often struggle to induce potent CD8+ T cell immunity.
• Malaria is a key target disease for improved CD8+ T cell-inducing vaccines, offering controlled human challenge studies for efficacy assessment.

Purpose of the Study:

• To review a heterologous prime-boost vaccination strategy for inducing high-level CD8+ T cell responses.
• To assess the potential of this approach for infectious disease immunization, including malaria.
• To evaluate the immunogenicity of this prime-boost strategy in preclinical models and ongoing human trials.

Main Methods:

• Identification and review of a heterologous prime-boost immunization regime.
• Utilizing DNA priming followed by recombinant modified vaccinia Ankara (MVA) boosting.
• Assessment of T cell responses in mice and non-human primates.

Main Results:

• The DNA prime and MVA boost strategy successfully induced high-level T cell responses in both mice and non-human primates.
• This approach demonstrates potential as a generic method for enhancing CD8+ T cell immunity.
• Clinical trials are underway to determine human immunogenicity.

Conclusions:

• A heterologous prime-boost approach using DNA and MVA is a promising strategy for inducing potent CD8+ T cell responses.
• This vaccination method holds potential for developing next-generation vaccines against challenging infectious diseases like malaria.
• Further clinical evaluation is necessary to confirm its efficacy and safety in humans.